Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Debt / NOTE 2.500% 3/1
-
Market price (% of par)
-
96.13%
-
Total 13F principal
-
$527,312,610
-
Principal change
-
+$11,268,325
-
Total reported market value
-
$516,889,796
-
Number of holders
-
40
-
Value change
-
+$21,523,566
-
Number of buys
-
23
-
Number of sells
-
18
Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 as of Q3 2023
As of 30 Sep 2023,
BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 was held by
40 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$527,312,610
in principal (par value) of the bond.
The largest 10 bondholders included
BRAIDWELL LP, ARISTEIA CAPITAL LLC, Graham Capital Management, L.P., Linden Advisors LP, ADVENT CAPITAL MANAGEMENT /DE/, HIGHBRIDGE CAPITAL MANAGEMENT LLC, D. E. Shaw & Co., Inc., WELLS FARGO & COMPANY/MN, Affinity Asset Advisors, LLC, and Voya Investment Management LLC.
This page lists
41
institutional bondholders reporting positions
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.